title: Overexpression of Eag1 potassium channels in clinical tumours.
abstract: BACKGROUND
  Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques.
  
  
  RESULTS
  The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA).
  
  
  CONCLUSIONS
  Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.
authors.affiliation: Department of Pathology, Georg-August University, Göttingen, Germany. hemmer@med.uni-goettingen.de
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hemmerlein
authors.forename: Rüdiger M
authors.initials: RM
authors.lastname: Weseloh
authors.forename: Fernanda
authors.initials: F
authors.lastname: Mello de Queiroz
authors.forename: Hendrik
authors.initials: H
authors.lastname: Knötgen
authors.forename: Araceli
authors.initials: A
authors.lastname: Sánchez
authors.forename: María E
authors.initials: ME
authors.lastname: Rubio
authors.forename: Sabine
authors.initials: S
authors.lastname: Martin
authors.forename: Tessa
authors.initials: T
authors.lastname: Schliephacke
authors.forename: Marc
authors.initials: M
authors.lastname: Jenke
authors.lastname: Heinz-Joachim-Radzun
authors.forename: Walter
authors.initials: W
authors.lastname: Stühmer
authors.forename: Luis A
authors.initials: LA
authors.lastname: Pardo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D001943:Breast Neoplasms / Q000378:metabolism; D016466:CHO Cells; D003110:Colonic Neoplasms / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D051638:Ether-A-Go-Go Potassium Channels / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000378:metabolism; D008297:Male; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D012142:Respiratory Tract Neoplasms / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D046888:Tissue Array Analysis; D014162:Transfection; D015854:Up-Regulation
chemical_list: D000911:Antibodies, Monoclonal; D051638:Ether-A-Go-Go Potassium Channels; C496884:KCNH1 protein, human; C485729:KCNH5 protein, human; D012333:RNA, Messenger